Nano-Megestrol Acetate for Cancer Cachexia in Advanced Pancreatic Cancer

Cancer anorexia-cachexia syndrome is a common and severe complication in patients with advanced cancer, with a particularly high prevalence in pancreatic cancer. It is associated with systemic inflammation, metabolic disturbances, and dysregulation of central appetite control, leading to reduced quality of life, poor tolerance to anticancer therapy, and shortened survival. Anticancer treatments, including chemotherapy and immunotherapy, may further exacerbate the development and progression of cachexia. Megestrol acetate is recommended as a first-line treatment for cancer-related anorexia-cac

Trial Details

NCT ID
NCT07408505
Phase
NA
Sponsor
Shandong Cancer Hospital and Institute
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • Nano-crystalline megestrol acetate
  • First-line Chemotherapy
Locations (sample)
  • Jinan, China|36.66833,116.99722

Key Eligibility Criteria

  • Patients must meet all of the following criteria to be eligible for enrollment:
  • 1\. Pancreatic cancer-specific inclusion criteria:
  • Histologically or cytologically confirmed locally advanced or metastatic pancreatic ductal adenocarcinoma according to the TNM staging system of th…
  • No prior systemic antitumor therapy for recurrent or metastatic disease;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →